23andMe

23andMe was co-founded by Anne Wojcicki (then married to Google co-founder Sergey Brin) with a revolutionary proposition: make DNA testing accessible to consumers for insights into ancestry, health risks, and genetic traits. The company was a cultural phenomenon, popularizing consumer genomics and building one of the world's largest genetic databases with over 14 million genotyped customers. In June 2021, 23andMe went public via SPAC at a valuation of $6 billion, backed by the promise that its massive genetic database would fuel a lucrative drug discovery business. The thesis was elegant: use the world's largest genetic dataset to identify drug targets, then license or develop therapeutics. But reality proved far harsher. The core consumer business was fundamentally challenged — genetic testing is a one-time purchase. Once you've spit in a tube and gotten your results, there's little reason to buy again. Subscription services for health insights attracted few paying customers. The drug discovery arm (23andMe Therapeutics) consumed hundreds of millions in R&D but produced disappointing results. In 2023, a massive data breach exposed the genetic and personal data of 6.9 million users, devastating consumer trust and resulting in a $30 million settlement. Throughout 2024, the situation deteriorated rapidly: the stock fell below $1 (triggering Nasdaq delisting warnings), all independent board members resigned en masse, the entire drug development pipeline was abandoned, and 75% of employees were laid off. CEO Anne Wojcicki proposed taking the company private but faced opposition. By late 2024, 23andMe was a penny stock with a market cap under $100 million — a 98%+ decline from its $6B SPAC valuation. The company that made DNA testing mainstream had proven that a massive dataset without a sustainable business model is just an expensive database.